INmuneBIO

United States
San Diego, California, United States, 92037

Company profile

INmuneBIO company profile

INmune Bio is a clinical-stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.

Business identity

Contact email
[email protected]
Phone number
(858) 964 3720
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0+
Founded
2015-01-01, Year

Headquarters

Postal code
92037
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
10
Total equity funding
$116.9M
Last funding
Post IPO Equity / $19M / 2025-06-27
Last equity funding
Post IPO Equity / $19M
Investors
3
Lead investors
3
Founders
3
Articles
90
Exited on
2019-01-15

Founders and investors

Founders

David MossMark LowdellRaymond Tesi

Lead investors

AlectorSilicon Valley BankToucan Capital

Investors

AlectorSilicon Valley BankToucan Capital